ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
Information provided by MedImmune LLC

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
Official Title  Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas
Brief Summary

RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells.

PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in treating patients with refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, or non-Hodgkin's lymphoma.

Detailed Description

OBJECTIVES:

  • Determine the maximum tolerated dose of recombinant BL22 immunotoxin in patients with CD22-positive refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, or indolent non-Hodgkin's lymphoma.
  • Determine the safety and efficacy of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Determine the immunogenicity of this drug in these patients.
  • Determine the effect of this drug on various components of the circulating cellular immune system in these patients.

OUTLINE: This is a nonrandomized, dose-escalation study. Patients are stratified according to disease type (chronic lymphocytic leukemia vs non-Hodgkin's lymphoma).

Patients receive recombinant BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5. Treatment repeats ≥ every 27 days for up to 6 courses in the absence of neutralizing antibodies to BL22 or PE38, disease progression, or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR. Patients who relapse from a CR lasting ≥ 6 months may receive additional courses.

Cohorts of 3-6 patients per stratum receive escalating doses of recombinant BL22 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: A total of 24 patients (12 per stratum) will be accrued for this study within 1-2 years.

Study Phase Phase I
Study Type  Interventional
Study Design  Treatment, Non-Randomized
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Leukemia
Lymphoma
Intervention  Drug: BL22 immunotoxin
Procedure: antibody-drug conjugate therapy
Procedure: immunotoxin therapy
MEDLINE PMIDs 16061911
Links Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site
Web site for additional information This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Active, not recruiting
Enrollment  24
Start Date  June 2005
Completion Date
Eligibility Criteria 

DISEASE CHARACTERISTICS:

  • Diagnosis of B-cell leukemia or lymphoma of 1 of the following types:

    • Chronic lymphocytic leukemia

      • Failed standard chemotherapy
    • Prolymphocytic leukemia

      • Failed standard chemotherapy
    • Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma

      • Stage III or IV disease
      • Failed ≥ 1 prior doxorubicin- or fludarabine-containing standard therapy
  • CD22-positive disease, as evidenced by 1 of the following:

    • More than 15% malignant cells react with anti-CD22 by immunohistochemistry
    • More than 30% malignant cells are CD22-positive by fluorescence-activated cell sorting analysis
    • More than 400 CD22 sites per malignant cell (average) by radiolabeled anti-CD22 binding
  • Treatment is medically indicated, as evidenced by any of the following:

    • Progressive disease-related symptoms
    • Progressive cytopenias due to marrow involvement
    • Progressive or painful splenomegaly or adenopathy
    • Rapidly increasing lymphocytosis
    • Autoimmune hemolytic anemia or thrombocytopenia
    • Increased frequency of infections
  • No neutralizing anti-toxin or anti-mouse immunoglobulin G (IgG) antibodies to BL22 or PE38

    • No serum neutralization of > 75% of the activity of 1 μg/mL of BL22
  • No CNS disease requiring treatment
  • No hairy cell leukemia

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • More than 6 months

Hematopoietic

  • Absolute neutrophil count > 1,000/mm^3*
  • Platelet count > 40,000/mm^3 NOTE: *Patients with leukemia are eligible regardless of absolute neutrophil count; Grade III-IV pancytopenia or growth factor dependence allowed if due to disease

Hepatic

  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • ALT and AST < 2.5 times ULN

Renal

  • Creatinine ≤ 1.5 mg/dL

Pulmonary

  • FEV1 ≥ 60% of predicted
  • DLCO ≥ 55% of predicted

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Prior bone marrow transplantation allowed
  • More than 3 weeks since prior biologic therapy, including interferon, denileukin diftitox, or LMB-2 immunotoxin
  • More than 3 months since prior monoclonal antibody therapy (e.g., rituximab)

Chemotherapy

  • See Disease Characteristics
  • More than 3 weeks since prior cytotoxic chemotherapy

Endocrine therapy

  • More than 1 week since prior steriods

    • Less than 5 doses for non-treatment reasons (e.g., allergy prophylaxis)
    • No evidence of disease response

Radiotherapy

  • More than 3 weeks since prior whole-body electron beam radiotherapy

    • Radiotherapy within the past 3 weeks allowed provided the volume of bone marrow treated is < 10% AND the patient has measurable disease located outside the radiation port

Surgery

  • Not specified

Other

  • More than 3 weeks since prior retinoids
  • More than 3 weeks since other prior systemic therapy for this malignancy
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00126646
Organization ID CDR0000438672
Secondary IDs †† NCI-05-C-0171, NCI-P6620, NCI-5336
Study Sponsor  MedImmune LLC
Collaborators ††
Investigators 
Principal Investigator:     Robert Kreitman, MD     National Cancer Institute (NCI)    
Information Provided By MedImmune LLC
Verification Date January 2007
First Received Date  August 2, 2005
Last Updated Date December 4, 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers